The Study Of The Expression Of CyclinE In Adult Acute Leukemia

Objective: The purpose is to study the expression of cyclinE in adult patients with acute leukemia, and evaluate the function and clinical value of cyclinE in acute leukemia.[Methods] The expression of cyclinE was measured in the bone marrow samples of 32 adult patients with acute leukemia and 20 control by S-P immunocytochemical method, and meanwhile 20 untreated cases. 2 relapsed cases and 10 cases in control group were examined by western-blot method. And analyse the relationship between the expression level of cyclinE and the progression and prognosis of adult patients with acute leukemia. [Results! The positive rate of cyclinE in 32 adult patients with acute leukemia was 71.8%. which is apparent higher than the control group with rate of 10%, there was significant difference between patients with acute leukemia and control group (P<0.001). The expression of cyclinE in acute lymphoblastic leukemia patients was higher than that in controls (P<0.0125), so was the expression of cyclinE in acute myelogenous leukemia patients. The positive rate of acute myelogenous leukemia patients (80%) was higher than that of acutelymphoblastic leukemia patients(64.7%), however, which had not significant difference between them (P=0.287) . The positive rate of cyclinE in untreated and relapsed patients (86.3%) was apparently higher than that of remission patients (40%) (P<0.05), and the remission rate in untreated patients with positive expression of cyclinE (28.6%) was lower than that in untreated patients with negative expression of cyclinE (84.6%), the difference between them was apparent (P<0.05) .[Conclusion] cyclinE had overexpression in adult acute leukemia patients. The expression level of cyclinE decreased when patients with acute leukemia were remission, and its expression level was correlated with the remission rate. Our results suggest potential roles of cyclinE in acute leukemia might be an oncogene, and the expression level of cyclinE is correlated with the progression and prognosis of patients with acute leukemia.